Pfizer 2009 Annual Report Download - page 104

Download and view the complete annual report

Please find page 104 of the 2009 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 110

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH(a)
2009
Revenues $10,867 $10,984 $11,621 $16,537
Costs and expenses 6,510 7,456 7,457 13,354
Acquisition-related in-process research and development charges —20— 48
Restructuring charges and certain acquisition-related costs(b) 554 459 193 3,131
Income from continuing operations before provision for taxes on
income 3,803 3,049 3,971 4
Provision/(benefit) for taxes on income 1,074 786 1,092 (755)
Income from continuing operations 2,729 2,263 2,879 759
Discontinued operations—net of tax 132 8
Net income before allocation to noncontrolling interests 2,730 2,266 2,881 767
Less: Net income attributable to noncontrolling interests 153—
Net income attributable to Pfizer Inc. $ 2,729 $ 2,261 $ 2,878 $ 767
Earnings per common share—basic(c):
Income from continuing operations attributable to Pfizer Inc.
common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Discontinued operations—net of tax ——— —
Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Earnings per common share—diluted(c):
Income from continuing operations attributable to Pfizer Inc.
common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Discontinued operations—net of tax ——— —
Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Cash dividends paid per common share $ 0.32 $ 0.16 $ 0.16 $ 0.16
Stock prices
High $ 18.48 $ 15.60 $ 16.98 $ 18.99
Low $ 11.62 $ 12.75 $ 14.11 $ 16.07
(a) In accordance with our domestic and international fiscal year-ends, approximately two-and-a-half months of Wyeth’s U.S. operations and
approximately one-and-a-half months of Wyeth’s international operations are included in our consolidated financial statements for the quarter ended
December 31, 2009. For additional information, see Note 2. Acquisition of Wyeth. The increase in revenues and costs and expenses in the fourth
quarter of 2009 primarily reflects the results of Wyeth’s operations as well as higher purchase accounting charges resulting from the Wyeth
acquisition.
(b) Restructuring charges and certain acquisition-related costs includes restructuring charges recorded in the fourth quarter of 2009 related to our
acquisition of Wyeth.
(c) Earnings per share in fourth-quarter 2009 was impacted by the increased number of shares outstanding in comparison with prior 2009 quarters,
resulting primarily from shares issued to partially fund the Wyeth acquisition.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
As of January 31, 2010, there were 239,543 holders of record of our common stock (New York Stock Exchange symbol PFE).
102 2009 Financial Report